Research graph
References from Activation of the EPO–EPOR axis enhances dopamine agonist sensitivity in prolactinoma through mitochondrial STAT5A–mediated suppression of mtDNA transcription. Local targets link to admitted publications; unresolved targets remain external evidence.
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019
10.1093/neuonc/noac202 · 2022 · External reference
Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification
10.1038/s41574-023-00883-8 · 2023 · External reference
Diagnosis and Management of Pituitary Adenomas: A Review
10.1001/jama.2023.5444 · 2023 · External reference
Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement
10.1038/s41574-023-00886-5 · 2023 · External reference
MicroRNAs in Dopamine Agonist-Resistant Prolactinoma
10.1159/000517356 · 2022 · External reference
Epidemiology and Management Challenges in Prolactinomas
10.1159/000497746 · 2019 · External reference
Management of Dopamine Agonist-Resistant Prolactinoma
10.1159/000495775 · 2019 · External reference
Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients
10.1530/eje-12-0236 · 2012 · External reference
The pathobiology of glioma tumors
10.1146/annurev-pathol-121808-102109 · 2010 · External reference
Exploring sex-specific hematological changes and their impact on quality of life in patients with prolactinoma
10.1007/s11102-024-01493-x · 2025 · External reference
Mayeux P. The molecular biology of erythropoietin
10.1093/ndt/14.suppl_2.22 · 1999 · External reference
Erythropoietin and cancer: the unintended consequences of anemia correction
10.3389/fimmu.2014.00563 · 2014 · External reference
The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression
10.1158/1078-0432.ccr-10-2577 · 2011 · External reference
Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions
10.1186/1756-8722-6-65 · 2013 · External reference
Erythropoietin Stimulates Tumor Growth via EphB4
10.1016/j.ccell.2015.09.008 · 2015 · External reference
Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro
10.1186/s13045-016-0306-x · 2016 · External reference
Erythropoietin improves the accumulation and therapeutic effects of carboplatin by enhancing tumor vascularization and perfusion
10.7150/thno.11304 · 2015 · External reference
Erythropoietin promotes the growth of pituitary adenomas by enhancing angiogenesis
10.3892/ijo.2011.1261 · 2012 · External reference
STAT5 as a Key Protein of Erythropoietin Signalization
10.3390/ijms22137109 · 2021 · External reference
Mitochondrial STAT5A promotes metabolic remodeling and the Warburg effect by inactivating the pyruvate dehydrogenase complex
10.1038/s41419-021-03908-0 · 2021 · External reference
Signal transducer and activator of transcription 5a (STAT5a) represses mitochondrial gene expression through direct binding to mitochondrial DNA
10.1016/j.bbrc.2020.04.152 · 2020 · External reference
Mitochondrial ROS drive foam cell formation via STAT5 signaling in atherosclerosis
10.1126/sciadv.adw9952 · 2025 · External reference
p300-mediated histone H3K18 lactylation promotes mitochondrial ROS accumulation via mitophagy inhibition to potentiate dopamine agonists efficacy in prolactinomas
10.1016/j.redox.2026.104077 · 2026 · External reference
Exploiting D(2) receptor beta-arrestin2-biased signalling to suppress tumour growth of pituitary adenomas
10.1111/bph.15504 · 2021 · External reference
Androgen Receptor Mediates Dopamine Agonist Resistance by Regulating Intracellular Reactive Oxygen Species in Prolactin-Secreting Pituitary Adenoma
2024 · External reference
Epobis is a Nonerythropoietic and Neuroprotective Agonist of the Erythropoietin Receptor with Anti-Inflammatory and Memory Enhancing Effects
10.1155/2016/1346390 · 2016 · External reference
Mitochondrial metabolism and cancer therapeutic innovation
10.1038/s41392-025-02311-x · 2025 · External reference
Mitochondrial DNA damage, repair, and replacement in cancer
10.1016/j.trecan.2024.09.010 · 2024 · External reference
Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth
10.1530/eje-14-0990 · 2015 · External reference
Dopamine agonist-resistant prolactinomas
10.3171/2010.11.jns101369 · 2011 · External reference
Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point
10.1093/gerona/glt154 · 2013 · External reference
Repurposing of erythropoietin as a neuroprotective agent against methotrexate-induced neurotoxicity in rats
10.1177/02698811241295379 · 2024 · External reference
Subchronic Intranasal Administration of NeuroEPO Reduces Long-Term Consequences of Severe Traumatic Brain Injury in Male Rats
2025 · External reference
Cyclic helix B peptide alleviates liver fibrosis via attenuating ROS-mediated pyroptosis
10.1016/j.intimp.2025.115439 · 2025 · External reference
Non-Erythropoietic EPO (EPO-R76E) Protects RPE Cells from Ferroptosis by Modulating the Labile Iron Pool and NRF2-GPX4 Axis
2026 · External reference
MLPH-mediated activation of dermal papilla IGF-1 signaling drives human hair shaft elongation and anagen induction
10.1016/j.biopha.2026.119114 · 2026 · External reference
Erythropoietin inhibits ferroptosis and ameliorates neurological function after spinal cord injury
10.4103/1673-5374.353496 · 2023 · External reference
Immuno-Metabolic Reprogramming by EPO Delivery System Accelerates Achilles Tendon Regeneration via Macrophage Polarization and Mitochondrial Rescue
2026 · External reference
A new agonist of the erythropoietin receptor, Epobis, induces neurite outgrowth and promotes neuronal survival
10.1111/j.1471-4159.2012.07751.x · 2012 · External reference
Pimozide augments bromocriptine lethality in prolactinoma cells and in a xenograft model via the STAT5/cyclin D1 and STAT5/Bcl‑xL signaling pathways
10.3892/ijmm.2020.4784 · 2020 · External reference
A disintegrin and metalloproteinase 22 activates integrin beta1 through its disintegrin domain to promote the progression of pituitary adenoma
10.1093/neuonc/noad148 · 2024 · External reference
